Cargando…

The Androgen Regulated lncRNA NAALADL2-AS2 Promotes Tumor Cell Survival in Prostate Cancer

Castration resistance is the leading cause of death in men with prostate cancer. Recent studies indicate long noncoding RNAs (lncRNAs) to be important drivers of therapy resistance. The aim of this study was to identify differentially expressed lncRNAs in castration-resistant prostate cancer (CRPC)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Groen, Levi, Yurevych, Viktor, Ramu, Harshitha, Chen, Johnny, Steenge, Lianne, Boer, Sabrina, Kuiper, Renske, Smit, Frank P., Verhaegh, Gerald W., Mehra, Niven, Schalken, Jack A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9787508/ https://www.ncbi.nlm.nih.gov/pubmed/36548180 http://dx.doi.org/10.3390/ncrna8060081

Ejemplares similares

Transcriptome Profiling of Circulating Tumor Cells to Predict Clinical Outcomes in Metastatic Castration-Resistant Prostate Cancer
por: Groen, Levi, et al.
Publicado: (2023)

Liquid biopsy reveals KLK3 mRNA as a prognostic marker for progression free survival in patients with metastatic castration‐resistant prostate cancer undergoing first‐line abiraterone acetate and prednisone treatment
por: Boerrigter, Emmy, et al.
Publicado: (2021)

Androgen receptor signalling confers clonogenic and migratory advantages in urothelial cell carcinoma of the bladder
por: Luna‐Velez, Maria V., et al.
Publicado: (2021)

RNA Biomarkers as a Response Measure for Survival in Patients with Metastatic Castration-Resistant Prostate Cancer
por: Boerrigter, Emmy, et al.
Publicado: (2021)

Delivery of antisense oligonucleotides for splice‐correction of androgen receptor pre‐mRNA in castration‐resistant prostate cancer models using cell‐penetrating peptides
por: Luna Velez, Maria V., et al.
Publicado: (2022)

Suppression of prostate tumor cell survival by antisense oligonucleotide-mediated inhibition of AR-V7 mRNA synthesis
por: Luna Velez, Maria V., et al.
Publicado: (2019)

Predictive and Prognostic Biomarker Identification in a Large Cohort of Androgen Receptor-Positive Salivary Duct Carcinoma Patients Scheduled for Combined Androgen Blockade
por: Lassche, Gerben, et al.
Publicado: (2021)

Enzalutamide: targeting the androgen signalling pathway in metastatic castration‐resistant prostate cancer
por: Schalken, Jack, et al.
Publicado: (2015)

Intratumoral steroidogenesis in castration-resistant prostate cancer: a target for therapy
por: Armandari, Inna, et al.
Publicado: (2014)

Clinical Pharmacokinetics and Pharmacodynamics of the Next Generation Androgen Receptor Inhibitor—Darolutamide
por: Podgoršek, Eva, et al.
Publicado: (2023)

Prediction of clinical benefit from androgen deprivation therapy in salivary duct carcinoma patients
por: van Boxtel, Wim, et al.
Publicado: (2019)

Androgen Receptor Pathway Activity Assay for Sepsis Diagnosis and Prediction of Favorable Prognosis
por: Bouwman, Wilbert, et al.
Publicado: (2021)

Pharmacological induction of translational readthrough of nonsense mutations in the retinoblastoma (RB1) gene
por: Palomar-Siles, Mireia, et al.
Publicado: (2023)

Noncoding RNAs as Novel Biomarkers in Prostate Cancer
por: Rönnau, C. G. H., et al.
Publicado: (2014)

Vulnerability and Resilience in the Caribbean Island States; the Role of Connectivity
por: Pereira, Edwina E., et al.
Publicado: (2021)

Cross-Resistance between Platinum-Based Chemotherapy and PARP Inhibitors in Castration-Resistant Prostate Cancer
por: Slootbeek, Peter H. J., et al.
Publicado: (2023)

Upregulation of miR-3195, miR-3687 and miR-4417 is associated with castration-resistant prostate cancer
por: Rönnau, C. G. H., et al.
Publicado: (2021)

Whole Blood Transcriptome Profiling Identifies DNA Replication and Cell Cycle Regulation as Early Marker of Response to Anti-PD-1 in Patients with Urothelial Cancer
por: van Wilpe, Sandra, et al.
Publicado: (2021)

Androgen Receptor-Activated Enhancers Simultaneously Regulate Oncogene TMPRSS2 and lncRNA PRCAT38 in Prostate Cancer
por: Chen, Zikai, et al.
Publicado: (2019)

LncRNA-Dependent Mechanisms of Androgen Receptor-regulated Gene Activation Programs
por: Yang, Liuqing, et al.
Publicado: (2013)

An androgen reduced transcript of LncRNA GAS5 promoted prostate cancer proliferation
por: Zhang, Yingyi, et al.
Publicado: (2017)

Analysis of the androgen receptor-regulated lncRNA landscape identifies a role for ARLNC1 in prostate cancer progression
por: Zhang, Yajia, et al.
Publicado: (2018)

Anabolic androgenic steroid abuse in young males
por: de Ronde, Willem, et al.
Publicado: (2020)

PCA3 and TMPRSS2-ERG: Promising Biomarkers in Prostate Cancer Diagnosis
por: Salagierski, Maciej, et al.
Publicado: (2010)

(68)Ga-PSMA-HBED-CC PET/CT imaging for adenoid cystic carcinoma and salivary duct carcinoma: a phase 2 imaging study
por: van Boxtel, Wim, et al.
Publicado: (2020)

Molecular Phenotyping of AR Signaling for Predicting Targeted Therapy in Castration Resistant Prostate Cancer
por: Hamid, Agus Rizal A. H., et al.
Publicado: (2021)

Anabolic–androgenic steroids: How do they work and what are the risks?
por: Bond, Peter, et al.
Publicado: (2022)

Prior PSMA PET-CT Imaging and Hounsfield Unit Impact on Tumor Yield and Success of Molecular Analyses from Bone Biopsies in Metastatic Prostate Cancer
por: Smits, Minke, et al.
Publicado: (2020)

Histopathologic Features of Breast Tissue From Transgender Men and Their Associations With Androgen Therapy
por: Wolters, Emily A, et al.
Publicado: (2022)

LncRNA HOTAIR Enhances the Androgen-Receptor-Mediated Transcriptional Program and Drives Castration-Resistant Prostate Cancer
por: Zhang, Ali, et al.
Publicado: (2015)

Application of lncRNA–miRNA–mRNA ceRNA network analysis in the treatment of androgenic alopecia
por: Wei, Hanxiao, et al.
Publicado: (2022)

Metabolomic effects of androgen deprivation therapy treatment for prostate cancer
por: Chi, Jen‐Tsan, et al.
Publicado: (2020)

Correction to: Impact of molecular tumour board discussion on targeted therapy allocation in advanced prostate cancer
por: Slootbeek, Peter H. J., et al.
Publicado: (2022)

Impact of molecular tumour board discussion on targeted therapy allocation in advanced prostate cancer
por: Slootbeek, Peter H. J., et al.
Publicado: (2021)

Assessing the economic impacts of IT service shutdown during the York flood of 2015 in the UK
por: Xia, Yang, et al.
Publicado: (2019)

Androgens and Androgen Receptor Actions on Bone Health and Disease: From Androgen Deficiency to Androgen Therapy
por: Chen, Jia-Feng, et al.
Publicado: (2019)

Plasma BRAF Mutation Detection for the Diagnostic and Monitoring Trajectory of Patients with LDH-High Stage IV Melanoma
por: Tolmeijer, Sofie H., et al.
Publicado: (2021)

Sex, androgens and regulation of pulmonary AR, TMPRSS2 and ACE2
por: Baratchian, Mehdi, et al.
Publicado: (2020)

Androgen regulation of the androgen receptor coregulators
por: Urbanucci, Alfonso, et al.
Publicado: (2008)

A Novel Androgen-Induced lncRNA FAM83H-AS1 Promotes Prostate Cancer Progression via the miR-15a/CCNE2 Axis
por: Liu, Bo, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ci4j3h6hjbs130vs7m9djth17q